Table 1

Patient characteristics

SAS (N=69)EAS (N=62)
Age58.0 (33.0, 76.0)58.0 (33.0, 76.0)
BMI, kg/m223.2 (16.5, 30.8)23.1 (16.5, 30.8)
Sex, n (%)
 Male38 (55.1)33 (53.2)
 Female31 (44.9)29 (46.8)
Ethnicity69 (100)62 (100)
 Chinese69 (100)62 (100)
ECOG PS
 03 (4.3)3 (4.8)
 166 (95.7)59 (95.2)
Smoking status
 Current or former smokers20 (29.0)17 (27.4)
 Never smoked49 (71.0)45 (72.6)
Tumor histology
 Adenocarcinoma68 (98.6)61 (98.4)
 NSCLC not otherwise specified1 (1.4)1 (1.6)
Site of metastasis
 Liver8 (11.6)5 (8.1)
 CNS13 (18.8)11 (17.7)
 Bone24 (34.8)22 (35.5)
Disease stage
 IIIB2 (2.9)2 (3.2)
 IV67 (97.1)60 (96.8)
Prior EGFR mutation type
 Exon 19 deletion39 (56.5)35 (56.5)
 Exon 21 L858R28 (40.6)26 (41.9)
 Others*2 (2.9)1 (1.6)
EGFR T790M mutation
 Positive20 (29.0)18 (29.0)
 Negative/unknown49 (71.0)44 (71.0)
Prior antitumor treatment
 Neoadjuvant/adjuvant10 (14.5)8 (12.9)
 1L systematic therapy65 (94.2)59 (95.2)
 2L systematic therapy32 (46.4)29 (46.8)
Prior EGFR TKI treatment
 First/second G TKI26 (37.7)23 (37.1)
 Third G TKI9 (13.0)7 (11.3)
First/second G TKI+ third G TKI34 (49.3)32 (51.6)
Prior anti-angiogenesis treatment
 Yes22 (31.9)18 (29.0)
 No47 (68.1)44 (71.0)
Prior systematic chemotherapy†
 Yes12 (17.4)11 (17.7)
 No57 (82.6)51 (82.3)
  • Data are the median (range) and n (%).

  • *Others including patients with G719X or L861Q mutation.

  • †Patients received prior monotherapy or limited courses of doublet chemotherapy for advanced NSCLC.

  • CNS, central nervous system; EAS, efficacy analysis set; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; G, generation; 1L, first line; 2L, second line; NSCLC, non-small cell lung cancer; SAS, safety analysis set; TKI, tyrosine kinase inhibitor.